Experimental drug that eradicates flu virus in 24 hours
Representatives of the Japanese pharmaceutical company Shionogi announced that an experimental agent has been developed in their laboratories that can deal with the flu virus in just 24 hours.
According to a Japanese pharmaceutical manufacturer , their new flu drug works faster than any other formulation on the market, with just one dose of the drug effectively eradicating the virus in a single day. The experimental drug is not yet available and is called baloxavir marboxil.
In the Phase 3 clinical trial, the time it took the drug to clear the influenza virus from the adult body was just over 24 hours. In por naniu, one of the most commonly used agents against influenza – oseltamivir, sold under the name Tamiflu and manufactured by the Swiss company Roche, takes about 72 hours to do its job.
However, this does not mean that those taking the new specific will immediately feel relief. Og lny time to alleviate the symptom was similar regardless of whether study participants took baloxavir marboxil or oseltamivir. However, Shionogi’s formulation deals with the virus much faster, which may reduce the risk of infection.
Baloxavir marboxil works through a different biological mechanism than oseltamivir. Oseltamivir is a neuraminidase inhibitor. It blocks the enzyme, which ry is used by the virus to leave the infected cell rka and the spread of. Baloxavir marboxil leverages discoveries made while working on drugs against HIV. It targets a different type of enzyme and prevents the vulnerability of the com rek for viral infections.
What’s more, according to its manufacturers, a single dose is enough for baloxavir marboxil to deal with the flu, while Tamiflu must be taken twice a day for five days.
The drug, developed by Shionogi, targets zar both against influenza A and B viruses. A few days ago, manufacturers received the green light from the Japanese government, indicating that the product should soon be on the market in Japan.
Japanese manufacturers will wsp lpork with Roche, which ra will have the right to distribute the new preparation internationally. The company will seek approval to sell the drug in the state in the United States in a few months. The decision should come next year, so the drug is not expected to appear on European markets earlier than 2020. However, until then, we can protect ourselves by regular vaccination, which re still the best option at the beginning of each flu season.